Publications by authors named "Thomas M Polasek"

Claim this Profile
R
Reply to "Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data".
John O Miners, Thomas M Polasek

Clin Pharmacol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et al.
John O Miners, Thomas M Polasek

Clin Pharmacol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN-3143, a Novel Inhibitor of Mono-Adenosine Diphosphate Ribosyltransferase-PARP14.
Thomas M Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak

Clin Pharmacol Drug Dev· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Povidone-iodine nasal spray (Nasodine) for the common cold: a randomized, controlled, double-blind, Phase III clinical trial.
Thomas M Polasek, Peter L Friedland

Front Med (Lausanne)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using pharmacogenomics to personalise drug therapy: which drugs, when and how.
Sophie L Stocker, Thomas M Polasek

Aust Prescr· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
A James M Daveson, Richard Stubbs, Thomas M Polasek, Jorma Isola, Robert Anderson

Lancet Gastroenterol Hepatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards.
Ivan Tiryannik, Aki T Heikkinen, Iain Gardner, Anthonia Onasanwo, Masoud Jamei, Thomas M Polasek

Clin Pharmacokinet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Pharmacogenetics of psychiatric disorders.
Sarah Allegra, Silvia De Francia, Stefano Comità, Maria Grazia Morgese, Thomas M Polasek

Front Genet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Population-Level Targets for Drug Concentrations: Precision Dosing Needs Individual-Level Targets that Include Superior Biomarkers of Drug Responses.
Thomas M Polasek, Richard W Peck

Clin Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone-iodine nasal spray (Nasodine).
Peter L Friedland, Thomas M Polasek, Duncan Topliss

Int Forum Allergy Rhinol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances Addressing the Challenges of Precision Dosing.
Iris K Minichmayr, Tomoyuki Mizuno, Srijib Goswami, Richard W Peck, Thomas M Polasek

Clin Pharmacol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Food on the Oral Absorption of N-Acetyl-D-Mannosamine in Healthy Men and Women.
Allan M Evans, Gianfranco Fornasini, Tahlia R Meola, William A Gahl, Marjan Huizing, Thomas M Polasek

Clin Pharmacol Drug Dev· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personality vulnerabilities and adverse event reporting in phase 1 clinical studies.
Joanna Skommer, Krish Gunesh, Thomas M Polasek

Trials· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis.
Kiflu G Tesfamicael, Lijun Zhao, Rubén Fernández-Rodríguez, David L Adelson, Michael Musker, Thomas M Polasek

Front Psychiatry· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia.
Sam Mostafa, Reza Rafizadeh, Thomas M Polasek, Chad A Bousman, Amin Rostami-Hodjegan

CPT Pharmacometrics Syst Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomics - a minor rather than major force in clinical medicine.
Thomas M Polasek

Expert Rev Clin Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
Richard T Kenney, John K Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Thomas M Polasek

Front Immunol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults.
Cecile Paquet Luzy, Emilie Doppler, Thomas M Polasek, Ruben Giorgino

Mol Genet Metab· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual twin for healthcare management.
Thomas M Polasek

Front Digit Health· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.
John O Miners, Thomas M Polasek, Julie-Ann Hulin, Andrew Rowland, Robyn Meech

Pharmacol Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the Efficiency of Clinical Pharmacology Studies.
Thomas M Polasek, Virna Schuck

Clin Pharmacol Drug Dev· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Thomas M Polasek, Indika Leelasena, Irina Betscheider, Marija Marolt, Hella Kohlhof

Clin Pharmacol Drug Dev· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistent terminology for medication-related problems in pharmacogenomic cases.
Thomas M Polasek, Sam Mostafa, Carl M J Kirkpatrick

J Psychiatry Neurosci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care.
Sibel Saya, Patty Chondros, Anastasia Abela, Cathrine Mihalopolous, Mary Lou Chatterton, Thomas M Polasek

Trials· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calculation of the pharmacogenomics benefit score for patients with medication-related problems.
Thomas M Polasek

Front Genet· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis